Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR)alpha activator, in non-human primates.
K-111 has been characterized as a potent peroxisome proliferator-activated receptor (PPAR)alpha activator. Antidiabetic potency and amelioration of disturbed lipid metabolism were demonstrated in rodents, which were accompanied by elevations of peroxisomal enzymes and liver weight. To examine the possible therapeutic application of K-111 we have now assessed its efficacy in non-human primates with high transferability to humans. For this purpose obese, hypertriglyceridaemic, hyperinsulinaemic prediabetic rhesus monkeys were dosed sequentially with 0, 1, 3 and 10mg/kg per day orally over a period of 4 weeks each. In addition, the effect of K-111 on the peroxisome compartment was analyzed in cynomolgus monkeys using liver samples obtained following a 13-week oral toxicity study. In prediabetic monkeys, the reduction of hyperinsulinaemia and improvement of insulin-stimulated glucose uptake rate indicated amelioration of insulin resistance. These effects were nearly maximal at a dose of 3mg/kg per day, while triglycerides and body weight were lowered significantly in a dose-dependent manner. This reduction of body weight contrasts sharply with the adipogenic response observed with thiazolidinediones, another family of insulin-sensitizing agents. In young cynomolgus monkeys at a dosage of 5mg/kg per day and more, K-111 induced an up to three-fold increase in lipid beta-oxidation enzymes with an 1.5- to 2-fold increase in peroxisome volume density. This moderate increase in peroxisomal activity by K-111 in monkeys is consistent with its role as an PPARalpha activator and corresponds to the observations with fibrates in other low responder mammalian species. The increase in beta-oxidation may explain, at least in part, the lipid modulating effect as well as the antidiabetic potency of K-111. This pharmacological profile makes K-111 a highly promising drug candidate for clinical applications in the treatment of type 2 diabetes, dyslipidaemia, obesity and the metabolic syndrome.
Schäfer
Silke A
SA
Institute of Anatomy and Cell Biology II, University of Heidelberg, D69120 Heidelberg, Germany.
Hansen
Barbara C
BC
Völkl
Alfred
A
Fahimi
H Dariush
HD
Pill
Johannes
J
D042962:Acyl-CoA Oxidase / Q000378:metabolism; D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D004195:Disease Models, Animal; D005260:Female; D005947:Glucose / Q000378:metabolism; D006946:Hyperinsulinism / Q000188:drug therapy* / Q000209:etiology; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000209:etiology; D015151:Immunoblotting; D007150:Immunohistochemistry; D007850:Lauric Acids / Q000494:pharmacology / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000502:physiology; D008252:Macaca fascicularis; D008253:Macaca mulatta; D008297:Male; D009765:Obesity / Q000150:complications; D009929:Organ Size / Q000187:drug effects; D020675:Peroxisomes / Q000378:metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists* / Q000378:metabolism; D014157:Transcription Factors / Q000819:agonists* / Q000378:metabolism
C116893:2,2-dichloro-12-(p-chlorophenyl)-dodecanoic acid; D007850:Lauric Acids; D008055:Lipids; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D042962:Acyl-CoA Oxidase; D005947:Glucose